Page 17 - EASL Recommendations on Treatment of Hepatitis C 2015 - Summary
P. 17
Table 4A. Drug-drug interactions between Table 4B. Drug-drug interactions between
HCV DAAs and HIV antiretrovirals. HCV DAAs and illicit recreational drugs.
SIM DCV SOF SOF/ 3D SIM DCV SOF SOF/ 3D
LDV LDV
• •
Abacavir ••• • • Amphetamine ••• • •
Didanosine • Cannabis •
Emtricitabine ••• • • Cocaine ••• • •
Lamivudine • Diamorphine •
NRTIs Stavudine ••• • • Diazepam ••• •
Tenofovir • Gamma-hy- •
Zidovudine ••• • • droxybutyrate ••• •
Efavirenz • Ketamine •
Etravirine ••• • • MDMA (ecstasy) ••• • •
Nevirapine • Methamphetamine •
Rilpivirine ••• • Phencyclidine (PCP) ••• • •
• Temazepam •
Atazanavir; ataza- ••• •
navir/ritonavir •
Protease inhibitors NNRTIs • • • •* ••• •
Darunavir/ritonavir; • ••• •
darunavir/cobicistat ••• • • ••• •
• ••• •
Fosamprenavir ••• • • ••• •
Lopinavir • • • •* •
Saquinavir • • • •* •
Dolutegravir •
Entry/ Elvitegravir/cobi- • • • •* SIM, simeprevir; DCV, daclatasvir; SOF, sofosbuvir; SOF/LDV,
Integrase cistat sofosbuvir plus ledipasvir; 3D, ritonavir-boosted paritaprevir,
inhibitors Maraviroc • • • •* plus ombitasvir and dasabuvir.
Raltegravir • • • •* Colour legend. Green: No clinically significant interaction
• • • •* expected. Amber: Potential interaction which may require a
••• • dosage adjustment, altered timing of administration or additional
monitoring. Red: These drugs should not be co-administered.
• • • •*
o Some drugs may require dose modifications
••• • dependent on hepatic function. Please refer to the
••• • product label for individual drugs for dosing advice.
SIM, simeprevir; DCV, daclatasvir; SOF, sofosbuvir; SOF/LDV, o The symbol (green, amber, red) used to rank the
sofosbuvir plus ledipasvir; 3D, ritonavir-boosted paritaprevir, clinical significance of the drug interaction is based on
plus ombitasvir and dasabuvir. www.hep-druginteractions.org
*Known or anticipated increase in tenofovir concentrations with (University of Liverpool). For additional drug-drug
boosted regimens and with efavirenz and rilpivirine when given interactions and for a more extensive range of drugs,
sofosbuvir plus ledipasvir: caution and frequent renal monitoring detailed pharmacokinetic interaction data and dosage
needed.
Colour legend. Green: No clinically significant interaction adjustments, refer to the above-mentioned website.
expected. Amber: Potential interaction which may require a
dosage adjustment, altered timing of administration or additional
monitoring. Red: These drugs should not be co-administered.
o Some drugs may require dose modifications
dependent on hepatic function. Please refer to the
product label for individual drugs for dosing advice.
o The symbol (green, amber, red) used to rank the
clinical significance of the drug interaction is based on
www.hep-druginteractions.org
(University of Liverpool). For additional drug-drug
interactions and for a more extensive range of drugs,
detailed pharmacokinetic interaction data and dosage
adjustments, refer to the above-mentioned website.
16
HCV DAAs and HIV antiretrovirals. HCV DAAs and illicit recreational drugs.
SIM DCV SOF SOF/ 3D SIM DCV SOF SOF/ 3D
LDV LDV
• •
Abacavir ••• • • Amphetamine ••• • •
Didanosine • Cannabis •
Emtricitabine ••• • • Cocaine ••• • •
Lamivudine • Diamorphine •
NRTIs Stavudine ••• • • Diazepam ••• •
Tenofovir • Gamma-hy- •
Zidovudine ••• • • droxybutyrate ••• •
Efavirenz • Ketamine •
Etravirine ••• • • MDMA (ecstasy) ••• • •
Nevirapine • Methamphetamine •
Rilpivirine ••• • Phencyclidine (PCP) ••• • •
• Temazepam •
Atazanavir; ataza- ••• •
navir/ritonavir •
Protease inhibitors NNRTIs • • • •* ••• •
Darunavir/ritonavir; • ••• •
darunavir/cobicistat ••• • • ••• •
• ••• •
Fosamprenavir ••• • • ••• •
Lopinavir • • • •* •
Saquinavir • • • •* •
Dolutegravir •
Entry/ Elvitegravir/cobi- • • • •* SIM, simeprevir; DCV, daclatasvir; SOF, sofosbuvir; SOF/LDV,
Integrase cistat sofosbuvir plus ledipasvir; 3D, ritonavir-boosted paritaprevir,
inhibitors Maraviroc • • • •* plus ombitasvir and dasabuvir.
Raltegravir • • • •* Colour legend. Green: No clinically significant interaction
• • • •* expected. Amber: Potential interaction which may require a
••• • dosage adjustment, altered timing of administration or additional
monitoring. Red: These drugs should not be co-administered.
• • • •*
o Some drugs may require dose modifications
••• • dependent on hepatic function. Please refer to the
••• • product label for individual drugs for dosing advice.
SIM, simeprevir; DCV, daclatasvir; SOF, sofosbuvir; SOF/LDV, o The symbol (green, amber, red) used to rank the
sofosbuvir plus ledipasvir; 3D, ritonavir-boosted paritaprevir, clinical significance of the drug interaction is based on
plus ombitasvir and dasabuvir. www.hep-druginteractions.org
*Known or anticipated increase in tenofovir concentrations with (University of Liverpool). For additional drug-drug
boosted regimens and with efavirenz and rilpivirine when given interactions and for a more extensive range of drugs,
sofosbuvir plus ledipasvir: caution and frequent renal monitoring detailed pharmacokinetic interaction data and dosage
needed.
Colour legend. Green: No clinically significant interaction adjustments, refer to the above-mentioned website.
expected. Amber: Potential interaction which may require a
dosage adjustment, altered timing of administration or additional
monitoring. Red: These drugs should not be co-administered.
o Some drugs may require dose modifications
dependent on hepatic function. Please refer to the
product label for individual drugs for dosing advice.
o The symbol (green, amber, red) used to rank the
clinical significance of the drug interaction is based on
www.hep-druginteractions.org
(University of Liverpool). For additional drug-drug
interactions and for a more extensive range of drugs,
detailed pharmacokinetic interaction data and dosage
adjustments, refer to the above-mentioned website.
16
